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Drug development faces the double challenge of increasing costs and increasing
pressure on pricing. To avoid that lack of perceived commercial perspective will leave
existing medical needs unmet, pharmaceutical companies and many other stakeholders
are discussing ways to improve the efficiency of drug Research and Development.
Based on an international symposium organized by the Medical School of the University
of Duisburg-Essen (Germany) and held in January 2016, we discuss the opportunities
and challenges of three specific areas, i.e., public–private partnerships, adaptive designs
and big data. Public–private partnerships come in many different forms with regard
to scope, duration and type and number of participants. They range from project-
specific collaborations to strategic alliances to large multi-party consortia. Each of
them offers specific opportunities and faces distinct challenges. Among types of
collaboration, investigator-initiated studies are becoming increasingly popular but have
legal, ethical, and financial implications. Adaptive trial designs are also increasingly
discussed. However, adaptive should not be used as euphemism for the repurposing
of a failed trial; rather it requires carefully planning and specification before a trial starts.
Adaptive licensing can be a counter-part of adaptive trial design. The use of Big Data
is another opportunity to leverage existing information into knowledge useable for drug
discovery and development. Respecting limitations of informed consent and privacy is a
key challenge in the use of Big Data. Speakers and participants at the symposium were
convinced that appropriate use of the above new options may indeed help to increase
the efficiency of future drug development.
Keywords: drug development, public–private partnership, investigator-initiated studies, adaptive trial design,
big data, informed consent, privacy
BACKGROUND
In 2002 about 50% of all prescriptions in the U.S. were filled with generics; this has increased to 88%
in 2014 (Munos, 2016). Nevertheless, generics accounted for only 17% of total drug expenditure in
2014. In other words, the historic activity of the pharmaceutical industry has provided physicians
and patients with a treasure trove of medications which provide adequate treatment for many
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conditions at a rather low price. This historic success of the
pharmaceutical industry has developed into a challenge for its
future existence. For diseases with existing treatments, novel
treatments must provide improved efficacy and/or tolerability
to a major extent; minor improvements are no longer seen as
innovation and hence are not reimbursed at branded prices. On
the other hand, successful treatments are still lacking for many
diseases but this has a reason. Either they have proven difficult
to treat, for instance schizophrenia or progression of Alzheimer’s
disease, or they are rare or otherwise of unclear commercial value
as, for instance, antibiotics.
Drug development cost has steadily been soaring since the
1950s; actually, Research and Development (R&D) costs per
newly approved drug has linearly increased over time – on a
logarithmic scale with a doubling of costs approximately every
9 years (Scannell et al., 2012) (Figure 1). Accordingly, in contrast
to often quoted 1.6 billion US $ for developing a single drug, it
has been estimated that costs per drug brought to the market
in 1997–2011 is 4 billion US $ or more with a range of 3.7
billion incurred by Amgen (33.2 billion expenses for R&D with
a total of nine new drugs) to 11.8 billion incurred by Astra
Zeneca (59.0 billion for R&D with a total of five new drugs)
(Herper, 2012). The difference between the two estimates is
largely driven by attrition, i.e., the inclusion of costs for drugs
that failed in development. Industry has reduced attrition due to
aspects of pharmacokinetics and bioavailability but has been less
successful with other reasons of attrition such as drug efficacy;
commercial, toxicology, and clinical safety reasons for attrition
may even increase (Kola and Landis, 2004). Despite these
improvements, late-stage attrition rates remain at an estimated
75% (Grainger, 2015) and, hence, is a major cost-driver in drug
development. The societal demand for truly innovative drugs,
i.e., those addressing major unmet medical needs, is likely to
worsen this trend as “high innovation” is inherently associated
with “high risk” and, therefore, increases the probability of
attrition.
The combination of increasing costs of drug development
and largely capped budgets for medication challenges the current
business model of the pharmaceutical industry. Therefore, new
models for a more effective and less costly drug development
are needed. Some reported models focus on use of non-clinical
or translational data to improve predictions of safety (Bowes
et al., 2012) or efficacy (Dolgos et al., 2016). Others focus on
target-centric approaches, particularly for new biological entities
(Swinney and Anthony, 2011), more rapid paths to clinical
proof-of-concept (Owens et al., 2015), or attempts to identify
candidates for early termination, i.e., before the most expensive
late-stage clinical development starts (Peck et al., 2015), or
more systematic portfolio review to systematically challenge
development candidates (Cook et al., 2014). Of note, risk
mitigation is not only an important topic for the pharmaceutical
industry but also in academic drug discovery (Dahlin et al., 2015).
Even radical models, such as letting patients/subjects pay for
their participation in clinical trials (Emanuel et al., 2015) have
been proposed. Which, if any, of these new models will lead
to major improvements in the productivity of drug discovery
and development is a matter of debate. However, the fact that
many different approaches are tested shows that none of them
has proven to be the path of choice until now. Although more
new medicines were approved in 2015 by the US Food and Drug
Administration (Mullard, 2016a) or the European Medicines
Agency (European Medicines Agency, 2016; Mullard, 2016b)
than in several previous decades, the pressure between increasing
development costs per launched drug and largely capped societal
FIGURE 1 | Number of new drugs approved by the U.S. Food and Drug Administration per inflation-adjusted billion of US $ spent on Research and
Development. Reproduced with permission from Scannell et al. (2012).
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expense remains to challenge the existing business model of
major pharmaceutical companies.
Two possible avenues are frequently seen as promising
opportunities for a more cost-effective drug discovery and
development. One of them is co-operative models, which can
represent co-operation between pharmaceutical companies or
public–private-partnerships (PPP). As stated by Elias Zerhouni,
“we must acknowledge that no single institution, company,
university, country, or government has a monopoly on
innovation” (Zerhouni, 2014). Another is the emergence of big
data, be it derived from genomics or from accumulating health-
related data from various sources. Against this background,
experts from academia, industry, regulatory authorities and
patient organizations gathered in Berlin (Germany) on 29.-
30.1.2016 to discuss the impact and potential of co-operative
models and big data on the future of drug development.
This was the 4th annual symposium within a series entitled
“Pharmaceutical Medicine,” which was launched in 2013 by the
Medical School of the University of Duisburg Essen.
TYPES OF
PUBLIC–PRIVATE-PARTNERSHIPS
Partnerships help participants to do things neither could do alone
or to do them in a more cost-effective manner, as highlighted
by Theo Meert (Janssen, Beerse, Belgium). Thus, complex
challenges can hardly ever be addressed by a single academic
or commercial entity; partnerships allow pooling of expertise,
knowledge and resources and may lead to cross-fertilization.
This becomes obvious when it is considered that global annual
academic and commercial Research and Development (R&D)
expenditure in the life sciences is about 250 billion €, whereas
even large pharmaceutical companies invest only a couple of
billion, i.e., a low single digit percentage of the global investment
(Anonymous, 2015). Engagement in partnerships may help
companies to leverage their own investment against that of the
global community, albeit with the possible consequence that
revenue may also need to be shared.
Partnerships can be classified based on the types of
participants or on scope and duration of the project, which
may fall in the competitive or pre-competitive space. Each
of them comes with a specific balance of responsibilities
between the public and the private partner (Figure 2). At
the participant level, partnerships can involve collaboration
between companies. For instance, representing collaboration in
the competitive space, two companies may work together for the
development of companion diagnostics of precision medicines
(Fridlyand et al., 2013). Partnerships can also involve multiple
pharmaceutical companies, typically for pre-competitive aspects
of drug discovery and development. The TransCelerate initiative
in the US is an example of this (Gill, 2014).
More frequently, partnerships involve pharmaceutical
companies and public institutions, i.e., PPP. PPP not only assist
the pharmaceutical industry in improving its productivity; they
can also help to fund and sustain the development of academic
drug discovery capabilities that benefit society by improving the
value gained from publicly funded research (Tralau-Stewart et al.,
FIGURE 2 | Scale and scope of private and public responsibility in Public–Private-Partnerships. Reproduced with permission from Roehrich et al. (2014).
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2009). The almost exponential growth of publications on PPP
between 1990 and 2010 testifies to their increasing role (Roehrich
et al., 2014). Moreover, not only academic institutions but also
foundations increasingly engage in PPP (de Vrueh et al., 2014).
PPP can also operate in the competitive or the pre-competitive
space. Examples of pre-competitive PPP co-funded by multiple
companies, governments, academic institutions and foundations
are listed in Table 1. Other approaches include corporate
mini-labs at academic institutions such as the Mitsubishi Genetic
Therapies Centre at Imperial College, sponsored research such
as GSK’s academic Alternative Discovery Initiative at Imperial
College, or proof-of-concept funds such as Johnson & Johnson
collaboration with Imperial College (Tralau-Stewart et al., 2009).
Partnerships can also be classified based on scope and
intended duration, for instance project-based collaborations
between a company and a specific group of investigators,
strategic alliances between a company and an entire academic
institutions or large, multi-partner consortia such as those under
the umbrella of the Innovative Medicines Initiative (IMI) of the
European Union and the European Pharma Association EFPIA.
The benefits and challenges in the various types of partnerships
were discussed based on specific examples. Martin C. Michel
(Johannes Gutenberg University, Mainz, Germany) reported
on a case study, in which project-based collaborations with
various academic investigators were used in the development of a
first-in-class molecule, the β3-adrenoceptor agonist mirabegron,
now approved for the treatment of the overactive bladder
syndrome (Michel and Korstanje, 2016). In this case, project-
based collaborations with leading academic groups were used
to address evolving mechanistic understanding of the condition
to be treated, development and validation of tools (antibodies
and radioligands) to detect the drug target at the protein
level, impact of gene polymorphisms of the drug target and
questions of desensitization. This specific program also fostered
relationships with leading academic groups in the field and,
thereby, helped to build acceptance for a new treatment modality.
Key challenge in these collaborations were the alignment of
timelines in academic research with those of commercial drug
development and resolving legal issues in setting up contracts
between the partners. In a recent survey of academic investigators
engaging in project-based, non-clinical collaboration with the
pharmaceutical industry, complex contract negotiations were
seen as a major hurdle for collaboration, interestingly equally
being attributed to legal departments of companies and academic
institutions (Amiri and Michel, 2015). Other case studies of
project-based collaborations in drug development have recently
been reported (Modjtahedi et al., 2014; Michel et al., 2015).
Academic investigators engaged in non-clinical drug-related
research expressed strong interest in such collaborations (Amiri
and Michel, 2015). In a systematic analysis of non-clinical
publications presumably reflecting work performed concomitant
with commercial drug development, 75% of all such publications
had a corresponding author from academia (Köster et al., 2016b).
Thus, project-based collaborations between pharmaceutical
companies and individual academic groups are an important
component of translational drug development, but the specific
needs and approaches may vary considerably between projects,
even within a company (Köster et al., 2016a).
Strategic alliances between a single pharmaceutical company
and a single academic institution are another type of PPP. This
option was discussed by Ruth Wellenreuther [German Cancer
Research Center (DKFZ), Heidelberg, Germany] and Holger
Hess-Stump (Bayer, Berlin, Germany) based on the alliance
between their institutions (Wellenreuther et al., 2012). The
DKFZ is a mainly government funded organization founded
in 1964 with a strong track record in cancer research, as
exemplified by two of their researchers, Harald zur Hausen
and Stefan Hell, being awarded Nobel Prizes in Physiology
or Medicine in 2008 and 2014, respectively. The partnership
between DKFZ and Bayer is characterized by several features:
Firstly, it is non-exclusive. This means that both partners
maintain a range of other strategic partnerships. For instance,
DKFZ has such partnerships locally with academic institutions
such as the Heidelberg University Medical Center, nationally the
German Cancer Consortium, and internationally the Karolinska
Institute in Sweden and the National Cancer Institute in
the US, and commercial organizations such as IBM, Roche
and Siemens Healthcare. Bayer in turn also has a broad
spectrum of alliances with academic and commercial partners,
for instance in oncology including the MD Anderson Cancer
Center, Cancer Research UK, Takeda and Amgen. Second,
strategic alliances are long-term oriented, risk and reward
sharing agreements between partners with complementary
expertise and the shared goal to develop new treatment options.
They require significant contributions from both partners in
terms of content, resources and funding. This combination
TABLE 1 | Examples of pre-competitive public–private partnerships.
Name Purpose Region Website
Scottish Translational Medicine
Research Collaboration
Training in translational medicine and
therapeutics
Scotland http://stmti.mvm.ed.ac.uk
Innovative Medicines Initiative Strengthening of drug research and
development in Europe
European Union www.imi.europa.eu
Dundee Kinase Consortium Protein kinase research and screening Global www.kinase-screen.mrc.ac.uk
Structural Genomics Consortium Drug discovery related to under-studied
areas of human genome
Global www.thesgc.org
SNP Consortium Gene polymorphism research Global http://internationalgenome.org
Biomarker Consortium Biomarker identification and validation Global www.biomarkersconsortium.org
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allows pursuing highly complex and innovative projects that
single partners could not have handled on their own. The
alliance between DKFZ and Bayer HealthCare started in 2009.
Complementary expertise contributed by the partners include
a deep knowledge on the molecular mechanisms of cancer,
innovative target ideas, expertise in novel emerging research
areas, novel mechanistic assays and clinical expertise and ability
to perform clinical studies on the side of DKFZ; on the Bayer side,
it includes expertise in drug discovery and development, target
validation strategies, established technology platforms for target
validation, assay development for high-throughput screening,
compound library and medicinal chemistry, preclinical drug
development, regulatory approval process and marketing and
sales (Wellenreuther et al., 2012; Thong, 2016). As part of the risk
and reward sharing approach, the partners share funding of joint
projects for a total of so far 6 million Euro per year (currently
about 15 projects active). Since April 2013 a joint lab for cancer
immunotherapy is operative. Moreover, there is a range of joint
activities including organization of scientific conferences, joint
project teams, seminars and visits. Bayer has a licensing option
for the joint project results to develop projects into commercially
successful products, in which case the DKFZ will participate in
financial revenues. Both partners realize that alliances may fail.
Analysis of failing alliances in general has shown that this is
most often due to poor relationships between the partners, which
includes lack of understanding for cultural differences, poor trust,
poor communication and poor conflict resolution. The second
most frequent cause of alliance failure is poor legal and financial
terms. In contrast, poor strategy and business planning account
for only a minor fraction of alliance failures. As a conclusion,
the DKFZ/Bayer alliance has realized the strategic importance
of professional alliance management. This includes buy-in from
all management levels, high strategic fit and complementary
expertise, involvement of alliance managers from negotiation
phase until end of cooperation, awareness of the cultural
differences and drivers, clearly defined governance structures
and processes for interaction, dedicated resources from both
sides and regular communication (Lessel and Douglas, 2010).
In the DKFZ/Bayer alliance, there is a Joint Research Review
Committee, which recommends projects, and Joint Steering
Committee, which decides on budget. Both committees have
equal representation from both partners, and alliance managers
from both sides are part of each committee (Wellenreuther
et al., 2012). Since start of the alliance, more than 100 project
proposals have been received, more than 30 joint projects have
started and 20 milestones were achieved in 16 projects. One of
these projects will start clinical development in the near future.
Based on this experience, Ruth Wellenreuther and Holger Hess-
Stumpp identified a number of key success factors: collaboration
on equal foot level with close interaction, exchange of expertise
and mutual benefit and long-term perspective; the alliances
enabling scientists to translate their research into applications;
a framework agreement enabling quick setup of joint projects
(not requiring single project negotiations); low administrative
hurdles with streamlined and short decision processes; low
bureaucracy with fixed personnel and consumable rates and
flexibility in deployment of funds; incentives for successful
application, completion of milestones and appropriate reporting;
participation of departments and scientists of DKFZ in financial
revenues.
Partnerships involving multiple pharmaceutical companies
and multiple academic and other organizations were discussed
by Matthias Gottwald (Bayer, Berlin, Germany), based on the
example of IMI. IMI is an overarching scheme of the European
Union and the European Federation of Pharmaceutical Industry
Associations (EFPIA) (Laverty and Goldman, 2014). It has three
aims, to make the R&D process in Europe more innovative and
efficient, to enhance Europe’s competitiveness and to address
key societal challenges. IMI started in 2008 and is currently
planned to run through 2024. Over this entire time frame,
the European Union and the EFPIA members have pledged
more than 5 billion €, with half of this sum coming from
each side. The contribution from industry is largely provided
“in kind,” i.e., by making manpower, technologies and samples
available. In contrast, the contribution from the European Union
is provided “in cash” and distributed to the public partners in
the consortia. Such public partners include academic institutions,
patient organizations and regulatory authorities as well as small-
to-medium sized enterprises. Industry defines the overall scope of
the projects, and public consortia can apply for participation via
competitive calls. Bringing together the complementary expertise
of the different stakeholders and experts from across Europe
allows to address issues that none of the partners could or
would address alone. In the first phase of IMI (2008–2013)
with a budget of 2 billion €, more than 7000 researchers
representing 845 academic teams, 17 regulatory authorities, 26
patient organizations, 169 small-to-medium enterprises and 480
EFPIA teams have worked or currently are working together
in about 60 projects. These projects cover all parts of the
R&D value chain from drug discovery up to market access.
An example for a project improving the efficiency of the drug
discovery process is the EU Lead Factory1, in which seven
companies have shared compounds from their own libraries
to create a big joint library, complemented by specifically
synthesized compounds coming from the public consortium
partners, and linked to a central screening center which allows
to screen novel targets against this highly diverse library. By
using this approach several companies have already identified
novel compounds for their pipeline which they could not have
found in their own libraries. In the preclinical safety project
eTOX2 12 pharma companies and several public partners have
shared data from their preclinical in vivo toxicity studies thereby
creating the biggest database in this field. Together with newly
developed modeling and simulation approaches this allows a
better prediction of potential toxicity linked to novel compounds,
allowing to deselect development compounds with a safety risk
months earlier than today. The project Electronic Health Records
for Clinical Research EHR4CR3 has developed standards for
electronic health records and an IT infrastructure for clinical trial
feasibility studies against patient registered at multiple centers
1www.europeanleadfactory.eu
2www.etoxproject.eu
3www.ehr4cr.eu
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in an anonymized way, thereby offering the potential to avoid
protocol amendments at a later stage and to speed up patient
recruitment. And the Get Real project4 analyzed data used for
discussion with HTA agencies to develop a guidance for HTA
data collection during late clinical development with the aim
to increase the probability that the relevant required data for
a successful dialog with the agencies are collected early in the
process.
A significant share of the budget (39%) went to projects related
to infectious diseases. Other major areas of funding included
drug discovery, brain disorders, metabolic disorders, drug safety,
stem cells, cancer and data management. IMI projects have so far
identified more than 460 new biomarker candidates, developed
or standardized more than 50 new animal models, more than
100 new in vitro models and more than 100 new in silico models.
More than 20 new drug targets were identified and more than
25 new tools were established to facilitate drug development.
Data generation for a better understanding of diseases on a
molecular level and validation of a multitude of biomarkers and
other tools was done in more than 65 clinical trials including
more than 18,000 patients. Specific modular training programs,
e.g., for pharmacoepidemiology and pharmacovigilance (EU2P5,
Translational Safety Sciences (SafeSciMET6), and Medicines
Development (PHARMATRAIN)7 have been developed,
attended already by more than 1000 trainees. On the commercial
side, 13 new spin-offs were created, 6 trademarks established, 3
licensing deals made, and 7 projects commercialized. Moreover,
20 patent applications were filed, with 65% of them coming
from academia. The second phase of IMI (2014–2020) with
an increased joint budget of more than 3 billion €, will focus
on processes and tools to bring precision medicines faster to
the patients. To integrate the new opportunities resulting from
digital health activities, it will be open to non-EFPIA companies
such as those related to healthcare IT and medical devices.
IMI2 will improve funding for small-to-medium enterprises
to incentivize broadest possible participation of experts in the
respective areas. The overall success of IMI is also witnessed by
the fact that South Korea and Japan are starting similar programs
on a smaller scale. Examples of broad, multi-stakeholder PPPs
are listed in Table 1.
Investigator-Initiated Studies
A special form of PPPs, initiated by academia, is the so-
called investigator-initiated research, in case of clinical research
often referred to as investigator-initiated trials or investigator-
initiated studies (IIS) (Suvarna, 2012). Aspects of non-clinical
investigator-initiated research have been discussed in the
previous section and reviewed elsewhere (Modjtahedi et al., 2014;
Michel et al., 2015; Michel and Korstanje, 2016) Focusing on
clinical IIS, Stefan Schröder and Miriam Bach (Bayer, Berlin,
Germany) reported that the investigator is responsible for
initiating, managing and financing the study, following applicable
4www.imi-getreal.eu
5www.eu2p.org
6www.safescimet.eu
7www.pharmatrain.eu
laws and regulations. These include the rules of Good Clinical
Practice and Good Manufacturing Practice as well as article 2
(e) of the European Directive 2001/20/EC. Thus, the investigator
or his/her institution assumes full responsibility of the role
of sponsor of the study as defined by Good Clinical Practice
guidelines. Of note, funding from a pharmaceutical company for
an IIS must not be used for any other purpose. The legal aspects of
IIS were additionally covered by Sigrid Achenbach (Bayer, Berlin,
Germany). She emphasized that IIS must not be promotional but
be of scientific merit and promote legitimate research interests.
The role of a company in IIS is to provide scientific advice,
financial support and/or study drug. In the framework of an IIS, a
pharmaceutical company must not plan or conduct a study, draft
the study protocol or publication.
In most cases, IIS are performed following regulatory approval
of a new treatment and focus on specific subgroups of patients
within the approved indication or on potential new indications.
While IIS most often fall into the area of competitive research,
an IIS can also be co-funded by more than one company both on
competing or different products.
In view of the utility of IIS in obtaining additional knowledge
on effects of drugs, several companies have now created dedicated
websites that investigators can use to submit their specific
proposals. Similarly, academic institutions increasingly see IIS as
an important means to perform studies of interest, particularly
those not funded by government. As an example, Sein Schmidt
[Berlin Institute of Health (BIH), Berlin, Germany] presented the
BIH. This research institution has been created in 2015 by the
German Research Ministry, the state of Berlin and the Helmholtz
Society to integrate experimental and clinical expertise at the
Charité, one of the leading hospitals in Europe, and the Max
Delbrück Center, an important center in biomedical research.
This newly formed institute will focus on the translation of novel
findings from research into clinical application and back and
thereby also play a major role in IIS initiated and/or performed
in Berlin.
An even wider network of investigator-driven research is the
European Clinical Research Infrastructure Network (ECRIN8)
It was created in 2004 to become an organization that could
facilitate multinational clinical trials in Europe. ECRIN’s first
project (2004–2005) focused on strategy, the second (2006–
2008) on tools, and the third (2008–2012) on infrastructure
development. By 2013, ECRIN had become what it set out to
be: a non-profit organization, based on country membership,
supporting mostly academic sponsors and investigators across
Europe to overcome the barriers to multinational clinical
research, now including 80 sites in 23 countries.
While support of IIS may be attractive for a company, it
involves risks. For instance, lack of upfront planning could lead to
non-validated data unsuitable for publication. While insufficient
budget may not allow completion of an IIS, a too high budget
may be seen as undue influence by a company, raising issues
of compliance and anti-corruption laws. Other than these legal
implications, such issues may also damage the reputation of the
academic institution and the supporting company. A frequent
8www.ecrin.org
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discussion point in the determination of an appropriate IIS
budget is institutional overhead. While including overhead
is possible in principle it must be reasonable, particularly
considering that the investigator and not the company had
initiated the study.
ADAPTIVE APPROACHES
One approach to make drug development more cost-effective
is the use of adaptive trial designs, which was discussed by
Stefan Hantel (Boehringer Ingelheim, Ingelheim, Germany).
After the introduction of the overall idea of adaptive trial
design (Bauer and Köhne, 1994), this concept has been discussed
controversially. The term ‘adaptive trial design’ is used to describe
methodology that allows to change key design features of a
clinical study based on (unblinded) observed data within the
trial and concomitantly controlling the overall type I error
level. In draft guidance issued in February 2010, the FDA has
defined adaptive trial design as follows (U.S. Food and Drug
Administration, 2010): “For the purposes of this guidance, an
adaptive design clinical study is defined as a study that includes
a prospectively planned opportunity for modification of one or
more specified aspects of the study design and hypotheses based
on analysis of data (usually interim data) from subjects in the
study.” Thus, adaptive trial design has to be pre-specified in
the protocol of the study and should not be added during the
conduct of the study. ‘Adaptive trial design’ typically does not
refer to classic protocol amendments covering minor aspects
of a clinical trial such as modification or clarification of in-
and exclusion criteria. Adaptive trial design shall also not get
confused with adaptive licensing (see below). When considering
adaptive design, one must be aware of risks for trial integrity.
Thus, results of an interim analysis can potentially jeopardize
trial integrity and introduce bias if investigator and/or patients
become aware of interim results, which can influence their
decisions. It can also affect trial integrity if sponsor or steering
committee modifies trial characteristics. On statistical grounds,
an interim analysis can have an impact on the type I error due
to multiple testing. While stopping a trial for futility (Michel
et al., 2013) has likely no impact on the error level of the
trial, in can influence the validity of the results of the entire
program.
Sample size re-assessment can be based on re-assessment
of variability or of overall event rates in event-driven studies
and is usually regarded as lacking impact on type I error as
long as blinding is maintained. Sample size re-assessment of
unblinded data is a common adaptation and provides more
detailed information concerning treatment effect. This can be
handled statistically by the promising zone approach (Mehta and
Pocock, 2011). In this approach, the initial sample size calculation
is based on the assumed treatment effect and variability and the
targeted power of the study. The observed treatment effect will
be calculated in a pre-planned interim analysis, which allows
calculation of conditional power based on the observed treatment
effect. If the power is lower than planned (i.e., the observed
treatment effect smaller than expected), sample size may be
increased if the interim results are in a ‘promising zone’. If the
treatment effect is much smaller than expected, as expected or
higher, the trial continues as planned without adaptation. The
EXAMINE trial of cardiovascular outcomes in diabetic patients
treated with the dipeptidyl peptidase IV inhibitor alogliptin is
an example of adapted sample sizes (White et al., 2013). The
trial assessed first non-inferiority of alogliptin based on the
margins 1.8 and 1.3 followed by the option to test superiority.
The interim analysis for non-inferiority for the 1.3 margin was
scheduled after 550 observed events. As pre-specified in the study
protocol, sample size could be increased to 1300 events if the
results were ‘promising’ in the interim analysis. In this case, the
interim analysis did not suggest that the sample size should be
increased. The final analysis was based on 621 events in 5380
randomized patients with a hazard ratio of 0.96 with an upper
limit of the confidence interval of 1.16 (<1.3). The strength of
the adaptive design of the EXAMINE trial is illustrated by the
fact that a similar trial without adaptive design also showed non-
inferiority without showing superiority; however, that trial was
planned to observe 1040 events in 16,500 patients, i.e., required
much higher patient numbers leading to a longer trial duration
and greater trial cost (Bhatt and Mehta, 2016). Of note, it is
being recommended that details of adaptive trial design should
not be communicated to the investigators to avoid potential bias.
Rather, investigators should only be informed, that the trial will
randomize up to 13,000 patients and that the trial has the option
to show superiority.
Another example how adaptive trial design can speed up
clinical development is the idea of seamless phase II/III design.
This approach combines two stages, which traditionally are
represented by distinct trials. In the traditional approach,
the phase II study focuses on selecting the dose for the
confirmatory/pivotal trials, whereas the phase III studies confirm
efficacy/effectiveness and safety of the selected dose. In a seamless
design, the decision is made during the course of the trial
and implemented before the study is concluded, preferably
while the recruitment is still ongoing. Both stages can be
analyzed separately, which results in less concern for bias in
the estimators. Several methods exist to combine data obtained
in both stages (Figure 3). Seamless phase II/III design requires
careful considerations, especially if the two stages are using
different primary endpoints, e.g., a biomarker vs. survival, a
narrower vs. a broader population and/or different regions
where the patients are recruited. Such seamless design only is
appropriate if the combination of results obtained in both stages
make sense from a medical perspective.
Biomarker-based enrichment is another type of adaptive trial
design. This uses an (established) predictive biomarker to enrich
the patient population (Wang et al., 2007). Such trials start with
recruiting biomarker-positive and negative patients. Treatment
effects in the biomarker-negative patients are assessed at interim
analysis; if treatment in the control group is larger than with
the test drug and the difference exceeds a futility boundary,
the accrual of biomarker-negative patients will be terminated,
whereas biomarker-positive patients continue to be enrolled until
the planned sample size has been achieved. The key advantage
of this design is a larger power than in a non-adaptive design.
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FIGURE 3 | Comparison of traditional and seamless design of Phases II and III studies. Reproduced with permission of originator (Dr. S. Hantel, Boehringer
Ingelheim Pharma GmbH & Co KG).
A key limitation is that the number of accrued biomarker-positive
patients is larger than in a study testing positive patients only and,
accordingly, may lead to a longer trial duration.
In conclusion, adaptive trial design can lead contribute to
efficiency in drug development by shortening timelines. However,
three key conditions must be met to do so:
– The overall type I error should be strongly controlled.
– Opportunities for adaptation should be defined
prospectively.
– The time point of the interim analysis has to be planned
prospectively.
Overall, it is mandatory that investigators fully understand
these methods according to the FDA guideline. They also need
to realize that adaptive designs require more intensive planning
and discussion within the sponsor and between sponsor and
regulatory authorities. Interim analyses should be performed
independent of the trial team and results have to be kept
confidential. Extensive simulations prior to start of the trial
should inform the characteristics of the design. Moreover, the
confirmatory character of a study may become questionable if the
design involves too much adaptation. Under no condition should
adaptive design be used as an excuse for sloppy planning.
Based on the potential benefits of adaptive design, Solange
Rohou (Astra Zeneca, Paris, France) reported on the IMI project
Accelerated Development of Appropriate
Patient Therapies: A Sustainable, Multi-stakeholder Approach
from Research to Treatment-outcomes (ADAPT-SMART9),
which kicked off in June 2015. This project brings together
various pharmaceutical companies with regulatory authorities
(e.g., European Medicines Agency), health technology assessment
bodies (e.g., NICE, HAS), patient organizations (e.g., Eurordis,
European Patient Forum) and, as observers, payers. It is aimed
at facilitating and accelerating the availability of Medicines
Adaptive Pathways to Patients (MAPPs) and thereby fostering
access to beneficial treatments for the right patient groups
at the earliest appropriate time in the product life-span in a
sustainable fashion. The project has to identify tools and methods
that could help progress MAPPs while analyzing gaps and
barriers to the use of MAPPs and ultimately make corresponding
recommendations. For instance, a workshop on MAPPs selection
criteria has been organized in February 2016 at the request of
the Dutch regulatory authority as part of the Dutch presidency
of the EU Council, witnessing the high level of attention this
project is being given. There will also be specific discussions
involving Health Technology Assessment bodies and payers on
managed entry agreements of MAPPs products with potentially
9www.adaptsmart.eu
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great health benefits but considerable uncertainty that would
need to be adequately addressed. A key challenge when securing a
targeted MAPPs marketing authorization will be to ascertain that
commitments to generate additional data are met and that the
product will not be used off-label.
Solange Rohou addressed three misconceptions on the use
of adaptive pathways. Firstly, adaptive approaches will not
provide regulatory approval based on lower standards of
evidence. This generates a quid pro quo for drug developers.
Rather, evidence will increase over time where multiple decision
points change timing of patient access. Earlier market access
will be gained in exchange for continued monitoring and
label changes based on such monitoring. Second, adaptive
approaches will not necessarily be faster and cheaper than
traditional pathways. Timing will only be faster to a first
decision but overall may increase to enlarge the population
to benefit from the product, or if ongoing monitoring does
not leverage payer and clinical systems. This implies that the
entire development program through indication roll-out and
surveillance is agreed upon early. Third, patients will not gain
unfettered early access. Rather patients would likely participate
in tracking, registries and observational studies with associated
informed consent. The ADAPT-SMART consortium will be
successful if it identifies all opportunities and challenges to
active patient participation, while developing a clear roadmap to
operate MAPPs in the near future. It will require self-challenge
and the courage to experiment with the understanding that
there are many different views among stakeholders including
payers; there is the shared intention to do the best to find
solutions to make the concept viable and resolve open questions
together.
BIG DATA
The term “big data” has been coined in the mid-1990s by
John Mashey, a computer scientist at Silicon Graphics, but
remains ill-defined (Flockhart et al., 2016) as explained by
Wolfgang Renz (Columbia University, New York, NY, USA
and McGill University, Montreal, Canada). Most often “big
data” is used as an umbrella term to describe large amounts
of data in a general sense, which by virtue of their volume
may allow combination and analysis to uncover unexpected
patterns and hidden information. With respect to healthcare,
these data mostly come from physicians and hospitals, health
insurance companies, and pharmaceutical and medical device
R&D; however, they may also involve patient behavior and
sentiment as well as population and public health data. In
an even broader sense, they may also include data from
genomic sources and large scale phenotyping efforts (Syn et al.,
2016).
There is a plethora of opportunities stemming from the
use of big data, and turning them into practical uses is just
beginning. For instance, pharmaceutical and other healthcare
companies can apply big data analysis to aggregate information
from previous clinical trials to identify potential problems or
adverse events. Big data may also allow analysis of clinical data
in real time to incorporate insight gleaned from behavior of
similar drugs under development, something of potential interest
not only to pharmaceutical companies but also to regulatory
authorities. Analysis of real-world data such as insurance claims
can be seen as giving a voice to customers in evaluating drug
or device effectiveness. Another example is medical information
coming from life-style products such as wearables (Mombers
et al., 2016). Thus, big data offer opportunities along the
entire value change from exploring epidemiology, drug target
identification to clinical development (Schultz, 2013). Big data
may also influence healthcare decision making by reducing
waste and inefficiencies and indicate appropriate standardization
of care, thereby allowing cost savings. They also facilitate a
more customer-focused approach to communication (Mills and
Ghatty, 2012).
Non-medical sources such as data collected by Google or
Facebook may also allow analysis to provide individual health-
related information. A case making the news in early 2012
may illustrate this (Hill, 2012). The US store chain Target had
identified sets of customer behavior that in aggregation have
a high chance of detecting pregnancy and even forecasting a
likely delivery date, which can be used in sending targeted
advertisement to corresponding customers. This became public
when the father of a high-school student protested that his
daughter received pregnancy-related advertisements from Target.
Unknown to him but apparently rightly predicted by Target use
of consumer data, his teenage daughter was indeed pregnant.
In biomedical terms, one may conclude that Target apparently
had identified an unconventional but novel biomarker of
pregnancy.
The use of big data provides the opportunity to enable
experimentation, create new knowledge and transparency; this
may allow to customize and target products and services,
improve decision making and promote innovation. Turning this
potential into practice faces challenges. While some sources of
big data are well structured, many are highly heterogeneous
and very dispersed even if they were generated within a major
pharmaceutical company (Harris, 2013). Thus, strategies for data
management and data segregation are still being developed, as
is the capacity to generate and communicate knowledge from
big data. One can only imagine the difficulty of physician
scientists acting as referees for a manuscript submitted to a
major biomedical journal in judging the scientific quality of data,
if the algorithms they are derived from are intellectually and
mathematically highly complex and far away from daily medical
practice. Therefore, a major challenge in the use and analysis
of big data is to design a process how to present all of the
information in a manner accessible and understandable to users.
Alliances between classic data analysis companies such as SAS
and major pharmaceutical companies such as GSK are a logical
answer to these challenges (Munro, 2013). Other challenges
include the lack of a clear regulatory and legal framework for the
use of big data in drug development. This includes the privacy
rule in the Health Insurance Portability and Accountability
act in the US or data protection and privacy legislation. On
technical grounds, protecting data in centralized stores is another
potential challenge. The IMI has recently started to address
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these challenges via a so called Big Data for Better Outcomes
(BD4BO) program, in which data from various sources like
real life data, Electronic Health Records, clinical trials, patient
registries and others will be made available and novel approaches
for the analysis of these heterogeneous data will be developed. If
successful, this offers the opportunity to support better treatment
decisions and a better guidance for a more targeted development.
Of note, proof of efficacy and safety of new medications for
obtaining marketing authorization is likely to remain a domain of
randomized clinical trials. Big data may help to address questions
of healthcare efficiency but factors such as channeling and
utilization bias will need to be considered in the interpretation
of such data.
Informed Consent and Privacy
Perhaps the most important societal challenge in the use of big
data is building public trust among citizens and patients that
big data will be used in an appropriate manner and privacy will
be maintained (Larson, 2013). Moreover, the use of big data
and biobanks of human specimens raises fundamental questions
on the type and validity of informed consent. Ulla Ohlms
(PATH Biobank, Munich Germany) presented the patient view
on informed consent, specifically with regard to biobanking. She
highlighted that modern patients no longer obtain knowledge on
their condition and available treatments from the yellow press
but increasingly use the internet for information gathering. They
tend to have faith in molecular biology research and expect
tailored therapy based on molecular information. This infuses
the patient-physician relationship with more shared decision
making. In this spirit, the PATH Foundation has been established
in 2002 by members of the breast cancer union “mamazone
e.V.” as a patient-driven biobank for breast cancer. It is a
joint venture of physicians, scientists and patients to provide a
resource for breast cancer research. It aims to support cancer
research in academia and industry by providing biomaterials
linked to clinical data including follow-up information. It is a
non-profit organization but charges users of the specimens a
cost recovery fee. Presently, it has stored about 5000 samples
each from tumor and normal tissue and about 7500 serum
samples from more than 8000 patients (Waldmann et al., 2014).
Recent research has shown that consent procedures vary widely,
even within a country, and this variability includes factors
such as addressing right of withdrawal, genetic analysis and
transborder use (Hirschberg et al., 2013). The PATH foundation
has taken several steps to ensure full informed consent of donors.
This includes comprehensive written information and a clear
consent form with the option of additional information via
internet, e-mail and phone. The consent material and the PATH
foundation process for sample use have been reviewed by an
independent ethical committee, a medical lawyer and the state
privacy officer and are regularly controlled by PATH’s board of
trustees. Key issues are a consent for use in cancer research
in a broad definition, lack of time limits on storage, transfer
of property rights to the biobank, the right to withdraw at
any time and data protection by pseudonymization. To ensure
patient engagement and full transparency, donors receive a yearly
newsletter informing them about news about the biobank, latest
information from cancer conferences as well as projects involving
PATH samples. Moreover, projects using PATH samples and
resulting publications are listed on the internet10.
Based on this experience, Ulla Ohlms discussed which issues
in informed consent forms are important from a patient point of
view. One aspect is how samples will be used and what kind of
analysis is planned. Particularly when applied to whole genome
analysis, becoming increasingly frequent in cancer research (Syn
et al., 2016), the question arises whether and how incidental
findings shall be communicated to the donor (Bishop et al., 2016).
Other relevant issues include a definition which third parties
may use the samples and whether they may be used in countries
having privacy protection laws different from those where the
donor resides. As some of the issues around use of samples, for
instance the increase in whole genome sequencing, may not have
been foreseen at the time of obtaining a sample, the concept of
dynamic consent has developed (Kaye et al., 2015). This concept
connects patients and researchers to enable more efficient patient
recontact but remains to be widely implemented.
Stefan Brink (Data Protection Officer Rhineland-Palatinate,
Mainz, Germany) discussed the limits of informed consent
from a legal point of view. As privacy and data protection
laws differ considerably between legislations, he focused on
the situation in Germany. This has largely been shaped by a
1983 landmark ruling of the German Federal Constitutional
Court. It ruled that the German constitution “warrants the
capacity of the individual to determine in principle the disclosure
and use of his/her personal data.” Implementing the ruling
of the Constitutional Court, § 3 of the German Federal Data
Protection act defines “Personal data means any information
concerning the personal or material circumstances of an
identified or identifiable individual (the data subject).” The legal
definition challenges the use of big data, particularly related
to “identifiable.” The association and integration of various
sources of information may make an individual identifiable
in ways that had not been anticipated when that law was
enacted. Said §3 further defines “Special categories of personal
data means information on a person’s racial or ethnic origin,
political opinions, religious or philosophical convictions, union
membership, health or sex life.” It further states “Rendering
anonymous means the modification of personal data so that
the information concerning personal or material circumstances
can no longer or only with a disproportionate amount of time,
expense and labor be attributed to an identified or identifiable
individual.” When applying these definitions, anonymization
becomes almost impossible in big data. Therefore, use of
data collected under German legislation in big data analysis
may be violating German law. However, there is ongoing
discussion whether related to medical including genomic data the
public good may outweigh the benefits of keeping information
private.
As discussed by Jill Nina Theuring (Bayer, Berlin, Germany),
data protection laws cover the healthcare sector but are general
and have not been designed specifically for this sector. Progress in
the collection and use of big data is driven by rapid technological
10www.path-biobank.org
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advances in this field, and legislation cannot easily keep
up with the speed of the technological advances, not to
mention predict what those advances will be by the time the
legislation becomes effective. This legal framework is further
complicated by differences between global areas, within the
EU and even between local regulatory agencies in Germany.
The new European general data protection regulation, which
was adopted in April 2016 and will enter into force on May
25th 2018, is likely to include opening clauses permitting
deviations in member states. Taken together this situation
creates considerable legal uncertainty in the healthcare sector.
Such uncertainty leads to various individual approaches of
regulatory authorities. Dealing with this heterogeneity is costly
and time-consuming for those involved in biomedical research
and drug development, limits pan-European and global projects,
and may put institutions located in some EU member
states at a competitive disadvantage compared to those in
others.
The trend toward more personalized/stratified medicine
increases the need to obtain and process clinical data and
those obtained from human biospecimen. Preclinical research
activities including genome-wide association studies, whole
genome sequencing and genetic tests in conjunction with
biomarkers also contribute data. This trend is further promoted
by the requirements of regulatory authorities to provide data
supporting the use of biomarkers and companion diagnostics
in patient-tailored drugs. Data privacy laws are relevant for all
kinds of pharmaceutical activities from early research to real-life
evidence; academic research in this regard is similarly affected.
Therefore, an aligned understanding of legal requirements
between pharmaceutical companies, academics, contract research
organizations, regulatory authorities, ethical committees, data
protection officers and patients is crucial.
One step to face this challenge has been taken via so-
called Coordination and Support Action for the IMI2 BD4BO
program, to be launched in January 2017. This will drive the
health outcomes strategy of the BD4BO program, integrate
knowledge and disseminate findings, design approaches to ensure
sustainability of projects in the program, ensure consistency and
quality across projects and to bring and share expertise across all
diseases and themes. One key element of the work will be the
analysis of the data privacy environment in Europe and beyond
and the joint work on a harmonization of Informed Consent
across stakeholders and countries.
CONCLUSION
The rising cost of drug development (Herper, 2012; Scannell
et al., 2012) combining with increasing pressure on drug
pricing (Scannell, 2015) challenge current business models of the
pharmaceutical industry. Public–private partnerships, adaptive
designs and use of big data offer opportunities for greater
efficiency in drug development. Only the future will tell which
of these approaches has helped most. For the time being,
we feel that all of them are promising candidates to make
drug R&D more efficient; their best admix is likely to be
a project-specific question. However, these opportunities can
only be leveraged if the inherent limitations of each of these
are understood. For all of these areas it can be concluded
that it is no longer pharmaceutical industry in isolation that
will develop new drugs. Rather we propose that early dialog
between pharmaceutical companies, academic investigators,
regulatory authorities, health technology assessment bodies,
payers and, most importantly, patients will increasingly shape
the way new drugs are developed to address existing medical
needs.
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